Loading
A phase 2 trial of Izalontamab brengitecan, Pembrolizumab, Bevacizumab in cervical cancer and endometrial cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer is a phase 2 interventional study registered as NCT07054567 by Sichuan Baili Pharmaceutical Co., Ltd., with 96 participants planned, started 2025-08-21 and due to reach its primary completion in 2027-05. Interventions recorded: BL-B01D1, Pembrolizumab, Bevacizumab. Conditions listed: Cervical Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Anti-angiogenic therapy, Cervical cancer.
Shares Izalontamab brengitecan, Recurrent or metastatic cervical cancer, SystImmune / Sichuan Biokin, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Anti-angiogenic therapy, Cervical cancer.
Shares Advanced or recurrent endometrial cancer, Anti-angiogenic therapy, Endometrial cancer, Monoclonal antibodies.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced or recurrent endometrial cancer, Anti-angiogenic therapy, Endometrial cancer, Monoclonal antibodies.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Cervical cancer, Pembrolizumab.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Pembrolizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/